Eli Lilly (LLY) Accounts Payables (2016 - 2025)
Historic Accounts Payables for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $4.3 billion.
- Eli Lilly's Accounts Payables rose 4765.98% to $4.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 billion, marking a year-over-year increase of 4765.98%. This contributed to the annual value of $3.2 billion for FY2024, which is 2423.43% up from last year.
- Eli Lilly's Accounts Payables amounted to $4.3 billion in Q3 2025, which was up 4765.98% from $4.1 billion recorded in Q2 2025.
- In the past 5 years, Eli Lilly's Accounts Payables ranged from a high of $4.3 billion in Q3 2025 and a low of $1.4 billion during Q1 2022
- Over the past 5 years, Eli Lilly's median Accounts Payables value was $2.4 billion (recorded in 2023), while the average stood at $2.4 billion.
- Per our database at Business Quant, Eli Lilly's Accounts Payables tumbled by 1258.23% in 2022 and then skyrocketed by 4911.11% in 2023.
- Eli Lilly's Accounts Payables (Quarter) stood at $1.7 billion in 2021, then increased by 15.56% to $1.9 billion in 2022, then skyrocketed by 34.61% to $2.6 billion in 2023, then rose by 24.23% to $3.2 billion in 2024, then skyrocketed by 32.01% to $4.3 billion in 2025.
- Its Accounts Payables stands at $4.3 billion for Q3 2025, versus $4.1 billion for Q2 2025 and $3.4 billion for Q1 2025.